Profile of Gastrointestinal Involvement in Patients with Systemic Sclerosis

Overview

Journal Rheumatol Int

Specialty Rheumatology

Date 2011 Jul 20

PMID 21769490

Citations 20

Authors

T Schmeiser

P Saar

D Jin

M Noethe

A Muller

N Soydan

P D Hardt

C Jaeger

O Distler

E Roeb

R G Bretzel

U Muller-Ladner

Affiliations

Soon will be listed here.

Abstract

Systemic sclerosis (SSc) is a chronic autoimmune connective tissue disease. Of the numerous organ manifestations, involvement of the upper and lower gastrointestinal tract (GIT) appears to be the most frequent with regard to the clinical symptoms. However, as the frequency and clinical relevance of GI involvement in patients with SSc are not known in detail, the German network of the systemic sclerosis (DNSS) has developed a detailed questionnaire to evaluate the extent and profile of gastrointestinal involvement in SSc patients. The multi-symptom questionnaire was used at baseline and after 1 year in registered patients of the DNSS. In addition, the results were compared with gastrointestinal disorders in patients with SSc and other rheumatic diseases, as well as with the medical history of the patients. In total, 90 patients were included in the study. The results of the study show that in reality, a much higher (nearly all) percentage of (98,9%) patients than expected suffer from GI-symptoms, regardless of the stage of their disease. Of these, meteorism (87,8%) was the most common followed by coughing/sore voice (77,8%), heartburn (daytime 68,9%, nighttime 53,3%), diarrhea (67,8%), stomach ache (68,9%) and nausea (61,1%). Although SSc patients were treated according to the respective recommendations, only limited improvements with regard to GI-symptoms could be achieved after 1 year of follow-up. In addition, the study revealed that the multi-symptom questionnaire is a useful tool to contribute to identify the gastrointestinal sequelae in systemic sclerosis.

Citing Articles

Serum markers of microbial translocation and intestinal damage in assessment of gastrointestinal tract involvement in systemic sclerosis.

Pellicano C, Oliva A, Colalillo A, Gigante A, DAliesio E, Al Ismail D Clin Exp Med. 2024; 24(1):225.

PMID: 39294494 PMC: 11410972. DOI: 10.1007/s10238-024-01466-1.

A Multidisciplinary Approach as a Goal for the Management of Complications in Systemic Scleroderma: A Literature Review and Case Scenario.

Patrintasu D, Sarkozi H, Lupusor E, Vlangar I, Rotariu G, Renta I Diagnostics (Basel). 2023; 13(21).

PMID: 37958228 PMC: 10648338. DOI: 10.3390/diagnostics13213332.

Treatable Traits in Systemic Sclerosis.

Amati F, Bongiovanni G, Tonutti A, Motta F, Stainer A, Mangiameli G Clin Rev Allergy Immunol. 2023; 65(2):251-276.

PMID: 37603199 DOI: 10.1007/s12016-023-08969-x.

Risk of Malnutrition in Patients With Systemic Sclerosis-Associated Interstitial Lung Disease Treated With Nintedanib in the Randomized, Placebo-Controlled SENSCIS Trial.

Volkmann E, McMahan Z, Smith V, Jouneau S, Miede C, Alves M Arthritis Care Res (Hoboken). 2023; 75(12):2501-2507.

PMID: 37357024 DOI: 10.1002/acr.25176.

Functional disability and health-related quality of life among systemic sclerosis patients in Bangladesh.

Hossain S, Choudhury M, Haque M, Yeasmin S, Hossain F, Zaman M BMC Rheumatol. 2022; 6(1):60.

PMID: 36175976 PMC: 9524111. DOI: 10.1186/s41927-022-00291-x.

References

Jaovisidha K, Csuka M, Almagro U, Soergel K . Severe gastrointestinal involvement in systemic sclerosis: report of five cases and review of the literature. Semin Arthritis Rheum. 2005; 34(4):689-702. DOI: 10.1016/j.semarthrit.2004.08.009. View

Cohen S, Fisher R, Lipshutz W, Turner R, Myers A, Schumacher R . The pathogenesis of esophageal dysfunction in scleroderma and Raynaud's disease. J Clin Invest. 1972; 51(10):2663-8. PMC: 332965. DOI: 10.1172/JCI107084. View

Chung L, Krishnan E, Chakravarty E . Hospitalizations and mortality in systemic sclerosis: results from the Nationwide Inpatient Sample. Rheumatology (Oxford). 2007; 46(12):1808-13. DOI: 10.1093/rheumatology/kem273. View

Manetti M, Neumann E, Milia A, Tarner I, Bechi P, Matucci-Cerinic M . Severe fibrosis and increased expression of fibrogenic cytokines in the gastric wall of systemic sclerosis patients. Arthritis Rheum. 2007; 56(10):3442-7. DOI: 10.1002/art.22940. View

Caserta L, de Magistris L, Secondulfo M, Caravelli G, Riegler G, Cuomo G . Assessment of intestinal permeability and orocecal transit time in patients with systemic sclerosis: analysis of relationships with epidemiologic and clinical parameters. Rheumatol Int. 2003; 23(5):226-30. DOI: 10.1007/s00296-003-0286-3. View

Walker U, Tyndall A, Czirjak L, Denton C, Farge-Bancel D, Kowal-Bielecka O . Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials And Research group database. Ann Rheum Dis. 2007; 66(6):754-63. PMC: 1954657. DOI: 10.1136/ard.2006.062901. View

. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Arthritis Rheum. 1980; 23(5):581-90. DOI: 10.1002/art.1780230510. View

Wang S, Lan J, Chen D, Chen Y, Hsieh T, Lin W . Effects of cisapride on colonic transit in patients with progressive systemic sclerosis. Clin Rheumatol. 2002; 21(4):271-4. DOI: 10.1007/s100670200072. View

Khanna D, Hays R, Park G, Braun-Moscovici Y, Mayes M, McNearney T . Development of a preliminary scleroderma gastrointestinal tract 1.0 quality of life instrument. Arthritis Rheum. 2007; 57(7):1280-6. DOI: 10.1002/art.22987. View

10.

Szamosi S, Szekanecz Z, Szucs G . Gastrointestinal manifestations in Hungarian scleroderma patients. Rheumatol Int. 2006; 26(12):1120-4. DOI: 10.1007/s00296-006-0146-z. View

11.

Weber P, Ganser G, Frosch M, Roth J, Hulskamp G, Zimmer K . Twenty-four hour intraesophageal pH monitoring in children and adolescents with scleroderma and mixed connective tissue disease. J Rheumatol. 2000; 27(11):2692-5. View

12.

Mayes M, Lacey Jr J, Beebe-Dimmer J, Gillespie B, Cooper B, Laing T . Prevalence, incidence, survival, and disease characteristics of systemic sclerosis in a large US population. Arthritis Rheum. 2003; 48(8):2246-55. DOI: 10.1002/art.11073. View

13.

Saar P, Schmeiser T, Tarner I, Muller-Ladner U . [Gastrointestinal involvement in systemic sclerosis. An underestimated complication]. Hautarzt. 2007; 58(10):844-50. DOI: 10.1007/s00105-007-1380-3. View

14.

SJOGREN R . Gastrointestinal features of scleroderma. Curr Opin Rheumatol. 1996; 8(6):569-75. DOI: 10.1097/00002281-199611000-00012. View

15.

SJOGREN R . Gastrointestinal motility disorders in scleroderma. Arthritis Rheum. 1994; 37(9):1265-82. DOI: 10.1002/art.1780370902. View

16.

Franck-Larsson K, Hedenstrom H, Dahl R, Ronnblom A . Delayed gastric emptying in patients with diffuse versus limited systemic sclerosis, unrelated to gastrointestinal symptoms and myoelectric gastric activity. Scand J Rheumatol. 2004; 32(6):348-55. DOI: 10.1080/03009740410005016. View

17.

Czirjak L, Kumanovics G, Varju C, Nagy Z, Pakozdi A, Szekanecz Z . Survival and causes of death in 366 Hungarian patients with systemic sclerosis. Ann Rheum Dis. 2007; 67(1):59-63. DOI: 10.1136/ard.2006.066340. View